COVID-19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 3, 2020.
Of the Phase III trial, Fauci indicated that the majority of trial participants will be between the ages of 18 and 55, but will include elderly Americans that are most at risk of serious illness from COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 2, 2020.
CSL Behring has developed a number of strategies to address COVID-19, the disease caused by the novel coronavirus that originated in China and spread across the globe in a matter of months.
U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn recently gave a speech to the Alliance for a Stronger FDA. In it, he suggested that some of the changes forced on the agency by the COVID-19 pandemic are likely to become permanent.
Emergent BioSolutions, a contract development and manufacturing organization, announced it had signed a public-private partnership under Operation Warp Speed worth about $628 million.
In the 5-day remdesivir group, patients were 65% more likely to see clinical improvement at 11 days compared to those treated with standard-of-care only.
The two companies were able to get their antibody candidate into the clinic within two months of announcing their collaboration in response to the global pandemic.
The San Francisco Business Times recently highlighted four women who are making strides in addressing the novel coronavirus in its “Influential Women of 2020” series.
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
PRESS RELEASES